DSIP (Delta Sleep Inducing Peptide): The Sleep and Opioid Withdrawal Peptide Under FDA Review
Regulatory Update (April 2026): DSIP (also referred to as Emideltide) is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026. The committee will evaluate DSIP for opioid withdrawal, chronic insomnia, and narcolepsy and consider it for the Section 503A Bulk Drug Substances List. Read our full coverage: FDA to Review 7 Peptides for Compounding List in July 2026.
Delta sleep inducing peptide, or DSIP, is a nine-amino-acid peptide first isolated in the 1970s from rabbit brain tissue. Researchers gave it that name because it appeared to promote the slow-wave brain activity associated with deep sleep. The FDA refers to it in the Federal Register as Emideltide. The agency will review DSIP for opioid withdrawal, chronic insomnia, and narcolepsy at its July 2026 Pharmacy Compounding Advisory Committee meeting.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Topic | Detail |
|---|---|
| What it is | Nine-amino-acid neuropeptide first isolated from rabbit brain tissue |
| Also known as | Emideltide (FDA terminology) |
| Research focus | Chronic insomnia, narcolepsy, opioid withdrawal, stress resilience |
| Mechanism | Not fully characterized; appears to modulate sleep-wake regulation and stress response |
| Administration | Subcutaneous injection or intranasal spray |
| FDA status | Not approved; under PCAC review July 24, 2026 for 503A Bulks List inclusion |
What Is DSIP?
DSIP is a neuropeptide that occurs naturally in the brain and other tissues. Swiss researcher Guido Monnier first isolated it in 1974 from the blood of sleeping rabbits. The name reflects its original observed effect: it promoted delta wave brain activity, the slow waves that dominate the deepest stages of sleep. Decades of subsequent research have broadened the picture. DSIP appears to play roles in stress response, pain modulation, hormonal regulation, and withdrawal from addictive substances. The FDA uses the name Emideltide in its Federal Register notice.
How DSIP Works
The exact mechanism of DSIP is still being worked out. Unlike many therapeutic peptides, DSIP does not have a single well-characterized receptor. Instead, it appears to influence multiple brain systems involved in sleep regulation and stress. Research has explored effects on cortisol release, neurotransmitter levels including serotonin and GABA, and autonomic nervous system tone. The lack of a single target has made DSIP harder to develop as a pharmaceutical, but the same versatility is partly why it has attracted research interest across different therapeutic areas.
Research on Sleep and Insomnia
The original reason DSIP was studied was its effect on sleep. Early clinical research in the 1980s showed that DSIP injections helped some patients with chronic insomnia fall asleep faster and improved sleep architecture. Unlike traditional sleep medications, DSIP does not appear to sedate. It seems to normalize sleep patterns rather than induce sleep through central nervous system depression. That profile could be attractive for patients who cannot tolerate benzodiazepines or Z-drugs, though published clinical trial data remains limited.
DSIP and Opioid Withdrawal
One of the most notable uses under FDA review is opioid withdrawal. Research from Russia and Eastern Europe, where DSIP has been studied more extensively than in the United States, has suggested the peptide may reduce withdrawal symptom severity and improve outcomes in opioid detoxification protocols. The mechanism appears to involve modulation of stress response pathways that are hyperactive during withdrawal. Given the ongoing opioid crisis, a peptide that could ease withdrawal without the addictive potential of other therapies would fill a meaningful clinical gap.
DSIP for Narcolepsy
The third use under review is narcolepsy. That application is less studied than insomnia or withdrawal. The rationale involves DSIP’s apparent role in stabilizing sleep-wake architecture. Narcolepsy is characterized by disruption of that architecture, particularly in the transition between wakefulness and REM sleep. Whether DSIP can meaningfully address the underlying dysregulation in narcolepsy is a question the PCAC review will likely examine.
Administration
DSIP is typically administered by subcutaneous injection. Some clinics use an intranasal formulation. The peptide crosses the blood-brain barrier to some extent, which is important for a compound intended to affect central nervous system function. Dosing protocols are highly individualized and should be managed by a clinician with experience in peptide therapy and the specific indication being treated.
Safety Profile
DSIP has a long history of human research and appears well tolerated. Reported side effects include mild drowsiness, headache, and injection site reactions. Because DSIP can influence cortisol and other hormones, patients with adrenal or thyroid disorders should be monitored closely. DSIP should not be combined with other sedating medications without physician oversight. As with any peptide not yet FDA-approved, long-term safety data remains limited.
What the FDA Review Could Mean
If PCAC recommends Emideltide for inclusion on the 503A Bulks List and the FDA acts on that recommendation, compounding pharmacies would have a clear legal path to dispense DSIP for patient-specific prescriptions. That would help patients with treatment-resistant insomnia, patients in structured opioid withdrawal programs, and potentially patients with narcolepsy who have not responded to standard medications. Public comment on the DSIP review can be submitted to FDA docket FDA-2025-N-6895 by July 9, 2026.
Cost and Finding a Provider
DSIP is not covered by insurance. Cash-pay costs vary by formulation and dose but typically run $200 to $400 per month. Use a licensed clinician who can evaluate the underlying cause of your insomnia or other condition before starting peptide therapy. Our peptide therapy directory lists verified clinics. For a broader overview of peptide therapy, see our complete guide to peptide treatments.
